As was reported on JDSupra, the Centers for Medicare and Medicaid Services (CMS) put forth in July 2023 a conclusive rule to rectify malpractices concerning traditional Medicare rates in the 340B Drug Pricing Program for the period 2018-2022.
The proposed resolution involves CMS making an approximate lump sum pay-out of $9 billion dollars to 340B providers, acting as a significant corrective measure to the past injustices. This fundamental-changing move occurs in the context of a program that grandstanded to reduce medication costs for covered entities, inadvertently finding itself at odds over muddled pricing and overpayments during the mentioned period.
The payout, although substantial, only pertains to traditional Medicare payments leaving the settlements concerning Medicare Advantage to be negotiated privately. This signifies an important aspect of the solution, pointing out that the CMS step solely resolves illegal traditional Medicare rates, and does not extend to privately negotiated rates within the Medicare Advantage landscape.
The implications this payout has within the broader landscape of Medicare and Medicaid should not be underestimated. CMS’s proactive approach towards rectifying pricing and overpayment issues could be indicative of an evolving landscape where healthcare becomes an increasingly regulated area with limited tolerance for illegality and financial mismanagement.